205 related articles for article (PubMed ID: 21447864)
21. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.
Lucky AW; Henderson TA; Olson WH; Robisch DM; Lebwohl M; Swinyer LJ
J Am Acad Dermatol; 1997 Nov; 37(5 Pt 1):746-54. PubMed ID: 9366821
[TBL] [Abstract][Full Text] [Related]
22. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188.
Vogler MA; Patterson K; Kamemoto L; Park JG; Watts H; Aweeka F; Klingman KL; Cohn SE
J Acquir Immune Defic Syndr; 2010 Dec; 55(4):473-82. PubMed ID: 20842042
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women.
Sekar VJ; Lefebvre E; Guzman SS; Felicione E; De Pauw M; Vangeneugden T; Hoetelmans RM
Antivir Ther; 2008; 13(4):563-9. PubMed ID: 18672535
[TBL] [Abstract][Full Text] [Related]
24. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20.
Hampton RM; Short M; Bieber E; Bouchard C; Ayotte N; Shangold G; Fisher AC; Creasy GW
Contraception; 2001 Jun; 63(6):289-95. PubMed ID: 11672549
[TBL] [Abstract][Full Text] [Related]
25. Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women.
Roy P; Jakate AS; Patel A; Abramowitz W; Wangsa J; Persiani S; Kapil R
J Clin Pharmacol; 2005 Mar; 45(3):329-36. PubMed ID: 15703367
[TBL] [Abstract][Full Text] [Related]
26. Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women.
Anderson MS; Hanley WD; Moreau AR; Jin B; Bieberdorf FA; Kost JT; Wenning LA; Stone JA; Wagner JA; Iwamoto M
Br J Clin Pharmacol; 2011 Apr; 71(4):616-20. PubMed ID: 21395656
[TBL] [Abstract][Full Text] [Related]
27. The effect of extending the pill-free interval on follicular activity: triphasic norgestimate/35 micro g ethinyl estradiol versus monophasic levonorgestrel/20 micro g ethinyl estradiol.
Creinin MD; Lippman JS; Eder SE; Godwin AJ; Olson W
Contraception; 2002 Sep; 66(3):147-52. PubMed ID: 12384201
[TBL] [Abstract][Full Text] [Related]
28. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment.
Thorneycroft lH; Gollnick H; Schellschmidt I
Cutis; 2004 Aug; 74(2):123-30. PubMed ID: 15379365
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic overview of Ortho Evra/Evra.
Abrams LS; Skee D; Natarajan J; Wong FA
Fertil Steril; 2002 Feb; 77(2 Suppl 2):S3-12. PubMed ID: 11849630
[TBL] [Abstract][Full Text] [Related]
30. Clinical experience with a new norgestimate-containing oral contraceptive.
Huber J
Int J Fertil; 1991; 36 Suppl 1():25-31. PubMed ID: 1678378
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.
von Hentig N; Müller A; Rottmann C; Wolf T; Lutz T; Klauke S; Kurowski M; Oertel B; Dauer B; Harder S; Staszewski S
Antimicrob Agents Chemother; 2007 Apr; 51(4):1431-9. PubMed ID: 17296738
[TBL] [Abstract][Full Text] [Related]
32. The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe.
Burger DM; Huisman A; Van Ewijk N; Neisingh H; Van Uden P; Rongen GA; Koopmans P; Bertz RJ
Clin Pharmacol Ther; 2008 Dec; 84(6):698-703. PubMed ID: 18528434
[TBL] [Abstract][Full Text] [Related]
33. Clinical comparison of triphasic norgestimate/35 micrograms ethinyl estradiol and monophasic norethindrone acetate/20 micrograms ethinyl estradiol. Cycle control, lipid effects, and user satisfaction.
Sulak P; Lippman J; Siu C; Massaro J; Godwin A
Contraception; 1999 Mar; 59(3):161-6. PubMed ID: 10382078
[TBL] [Abstract][Full Text] [Related]
34. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
Colombo S; Buclin T; Franc C; Guignard N; Khonkarly M; Tarr PE; Rochat B; Biollaz J; Telenti A; Decosterd LA; Cavassini M
Antivir Ther; 2006; 11(1):53-62. PubMed ID: 16518960
[TBL] [Abstract][Full Text] [Related]
35. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
Luber AD; Brower R; Kim D; Silverman R; Peloquin CA; Frank I
HIV Med; 2007 Oct; 8(7):457-64. PubMed ID: 17760738
[TBL] [Abstract][Full Text] [Related]
36. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
Griffith SG; Dai Y
Clin Ther; 2004 Dec; 26(12):2056-65. PubMed ID: 15823769
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers.
King JR; Kakuda TN; Paul S; Tse MM; Acosta EP; Becker SL
J Clin Pharmacol; 2007 Feb; 47(2):201-8. PubMed ID: 17244771
[TBL] [Abstract][Full Text] [Related]
38. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.
Song I; Borland J; Chen S; Lou Y; Peppercorn A; Wajima T; Min S; Piscitelli SC
Br J Clin Pharmacol; 2011 Jul; 72(1):103-8. PubMed ID: 21342217
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
Zhu L; Hruska M; Hwang C; Shah V; Furlong M; Hanna GJ; Bertz R; Landry IS
Antimicrob Agents Chemother; 2015 Jul; 59(7):3816-22. PubMed ID: 25870057
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve.
Bertz RJ; Persson A; Chung E; Zhu L; Zhang J; McGrath D; Grasela D
Pharmacotherapy; 2013 Mar; 33(3):284-94. PubMed ID: 23456732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
